Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study
Year: 2021
Type: article
Study design: Clinical Trial
Source: Cancer Immunology Immunotherapy
Institutions: Guangdong General Hospital, Guangdong Academy of Medical Sciences, Fujian Provincial Cancer Hospital, Zhejiang Cancer Hospital, Sir Run Run Shaw Hospital, Zhejiang University, Jiangsu Cancer Hospital, Nanjing Medical University, Shanghai Jiao Tong University, Shanghai Chest Hospital, First Affiliated Hospital of Zhengzhou University, Chinese PLA General Hospital, Chinese People's Liberation Army, First Affiliated Hospital of Nanchang University, Zhengzhou University, Henan Cancer Hospital, Jilin Province Tumor Hospital, Liaoning Cancer Hospital & Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, First Affiliated Hospital Zhejiang University, Guangdong Provincial People's Hospital, Peking University Cancer Hospital, Jiangsu Hengrui Medicine (China)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Jiangsu Hengrui Medicine
OpenAlex ID: W3205742112